Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-091720

Filed: 2026-08-19

Period: 2026-08-19

CIK: 0001468492

SIC: 6199 (FINANCE SERVICES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0302763-8k_heart.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 19, 2026 (ea030276301ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302763-8k_heart.htm · Sequence: 1

false

0001468492

2026-08-19

0001468492

us-gaap:CommonStockMember

2026-08-19

0001468492

HSCS:WarrantsMember

2026-08-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 19, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its

Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550 Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including

Area Code: (682) 237-7781

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

HSCS

The Nasdaq Stock Market LLC

Warrants

HSCSW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 19, 2026, HeartSciences

Inc. (the “Company” or “HeartSciences”) issued a press release announcing the consummation of the

previously reported sale and issuance to Fortitude Mining Holdings, Inc. (“Fortitude”) of an aggregate of 411,522 shares

(the “Shares”) of HeartSciences’ common stock, $0.001 par value per share, on August 12, 2026 at a purchase price of

$2.43 per Share in a private placement in connection with the expected closing of the previously reported proposed business combination

with Fortitude (the “Proposed Transaction”), a copy of which is furnished as Exhibit 99.1 to this Current Report

on Form 8-K (this “Current Report”).

The information provided in

this Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of HeartSciences under the

Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation

language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Additional Information and Where to Find It

Communications related to

each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in respect

of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy statement on Schedule

14A with the U.S. Securities and Exchange Commission (the “SEC”) on July 27, 2026 and may file additional relevant

materials with the SEC. Following the filing of a definitive proxy statement with the SEC, HeartSciences will mail the definitive proxy

statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS

AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT

DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE

BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE

INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR

ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The preliminary proxy statement, the definitive proxy statement

and other relevant materials in connection with the Proposed Transaction (when they become available), and any other documents filed by

HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders

may obtain free copies of the documents filed with the SEC or by sending a request to the HeartSciences Investor Relations Department

at investorrelations@heartsciences.com.

NEITHER THE SEC NOR ANY STATE

SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE

PROPOSED TRANSACTION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS CURRENT REPORT. ANY

REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Cautionary Note Regarding Forward-Looking Information

Communications may contain

forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements

generally can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,”

“could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,”

“project,” “potential,” “target,” “objective,” “intend,” and other words of

similar meaning, but the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or

Fortitude make in communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements

are based on management’s current expectations and assumptions as of the date of such communication and are subject to a number

of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed

or implied by such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be

completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including

obtaining the requisite approval of the HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely

affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management

of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price

of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding

digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the

forward-looking statements in such communications are discussed in HeartSciences’ filings with the SEC, including its Annual Report

on Form 10-K, filed with the SEC on July 23, 2026 and its other reports filed with the SEC from time to time, and are discussed in the

preliminary proxy statement filed by HeartSciences with the SEC in connection with the Proposed Transaction. Readers are cautioned not

to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to

update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by applicable law. Any forward-looking statements made in such communications are made as of the date of the communication.

Participants in the Solicitation

HeartSciences and Fortitude,

their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc., the parent company

of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the

Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the

Proposed Transaction, by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials filed or

that may be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained

herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation

to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval

in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities

in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and

conditions of the Merger Agreement, which contain the full terms and conditions of the Proposed Transaction.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Number

Description

99.1**

Press Release, dated August 19, 2026.

104**

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: August 19, 2026

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

President, Chief Executive Officer and Chairman of the Board of Directors

EX-99.1 — PRESS RELEASE, DATED AUGUST 19, 2026

EX-99.1

Filename: ea030276301ex99-1.htm · Sequence: 2

Exhibit 99.1

Fortitude Invests $1.0 Million in HeartSciences

at a 22% Premium with No Adjustment

to the Merger Consideration

Shares issued at $2.43, a 22% premium to the

closing price on the purchase date, with Fortitude receiving no additional merger consideration in respect of the investment

· Fortitude

purchased approximately $1,000,000 of HeartSciences’ shares of common stock at $2.43 per share, a 22% premium to the closing price

on the purchase date

· The

exchange ratio under the merger agreement with Fortitude is unchanged, and no additional shares will be issued to holders of Fortitude’s

equity interests at closing as a result of the investment

· Following

the investment, Fortitude holds approximately 9.4% of HeartSciences’ outstanding shares of common stock

Southlake, TX, August 19, 2026 (GLOBE NEWSWIRE)

-- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology

(“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration

of artificial intelligence (“AI”), today announced that on August 12, 2026 Fortitude Mining Holdings, Inc. (“Fortitude”)

purchased 411,522 shares of HeartSciences’ common stock for an aggregate purchase price of approximately $1,000,000 in a private

placement (the “Investment”). The shares were issued at a negotiated price of $2.43 per share, representing a 22% premium

to the closing price of HeartSciences’ common stock on the purchase date.

Fortitude purchased the shares for cash at a premium

to market price. The exchange ratio under the merger agreement between Fortitude and HeartSciences (the “Merger Agreement”)

is not adjusted as a result, and no additional shares will be issued to holders of Fortitude’s equity interests at closing in respect

of the amount invested. The shares issued in the Investment are voting shares of HeartSciences’ common stock and carry no additional

rights or preferences. Following the Investment, Fortitude holds approximately 9.4% of HeartSciences’ outstanding shares of common

stock.

The Investment provides additional working capital

to HeartSciences and strengthens its balance sheet ahead of the expected closing of the proposed business combination between Fortitude

and HeartSciences (the “Proposed Transaction”). The Proposed Transaction is expected to close in the second half of the current

calendar year and remains subject to customary closing conditions, including approval by HeartSciences’ shareholders.

Additional information regarding the Investment

is set forth in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”)

on August 18, 2026.

About Fortitude

Fortitude, currently wholly-owned by DCG, is an

institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash.

Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive long-term

contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work ecosystems,

beginning with its leadership position in the Zcash network. Fortitude is led by an experienced team of operators, capital markets professionals,

and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and building privacy-preserving

digital asset infrastructure.

For more information, visit www.fortitudemining.com

and follow Fortitude on X at @FortitudeCrypto.

About HeartSciences

HeartSciences is a healthcare information technology

company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™

Platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its

MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.

For more information, please visit www.heartsciences.com

and follow HeartSciences on X @HeartSciences.

Cautionary Note Regarding Forward-Looking Information

This press release may contain forward-looking

statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally

can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,”

“may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,”

“potential,” “target,” “objective,” “intend,” and other words of similar meaning, but

the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or Fortitude make in

communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on

management’s current expectations and assumptions as of the date of such communication and are subject to a number of known and

unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by

such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be completed on

the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining

the requisite approval of HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely affect either

HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management of a newly

public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price of Zcash

and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital

assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking

statements in such communications are discussed in HeartSciences’ filings with the SEC, including its Annual Report on Form 10-K,

filed with the SEC on July 23, 2026 and its other reports filed with the SEC from time to time, and are discussed in the preliminary proxy

statement filed by HeartSciences with the SEC in connection with the Proposed Transaction. Readers are cautioned not to place undue reliance

on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Any forward-looking

statements made in such communications are made as of the date of the communication.

Additional Information About the Proposed Transaction

and Where to Find It

Communications related to each of Fortitude and

HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in respect of the Proposed

Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy statement on Schedule 14A with the SEC

on July 27, 2026 and may file additional relevant materials with the SEC. Following the filing of a definitive proxy statement with the

SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special meeting

relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS

OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY

FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION.

COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS

ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The preliminary proxy

statement, the definitive proxy statement and other relevant materials in connection with the Proposed Transaction (when they become available),

and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov.

In addition, investors and shareholders may obtain free copies of the documents filed with the SEC by sending a request to the HeartSciences

Investor Relations Department at investorrelations@heartsciences.com.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY

AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE PROPOSED TRANSACTION OR

ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE HEREIN. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES

A CRIMINAL OFFENSE.

Participants in the Solicitation

HeartSciences and Fortitude, their respective

directors and executive officers, and certain executive officers of Digital Currency Group, Inc., the parent company of Fortitude, may

be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction.

Information regarding the identity of the potential participants, and their direct or indirect interests in the Proposed Transaction,

by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials filed or that may be filed with

the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained herein is not intended

to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise

acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction,

pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction

in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the Merger

Agreement, which contain the full terms and conditions of the Proposed Transaction.

Investor Relations and Media Contacts:

HeartSciences

Integrous Communications

Mark Komonoski

Phone: 877-255-8483

Email: mkomonoski@integcom.us

Fortitude

ICR

Phone: 917-375-9457

Email: IR@fortitudemining.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 19, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 19, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550 Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCS_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: